StockDriftsStockDriftsTop 8 Takeda Pharmaceutical Co Ltd Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| OVID | Ovid Therapeutics, Inc. | 59.82% | 7.53M | $9.8M | +0.00%(+0) | $3.43(-48.14%) | 2025-09-30 | |
| EQ | Equillium, Inc. | 15.94% | 1.82M | $2.6M | +0.00%(+0) | $0.58(+158.30%) | 2025-09-30 | |
| XLO | Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics) | 7.59% | 1.48M | $1.2M | +0.00%(+0) | $0.92(-27.93%) | 2025-09-30 | |
| STTK | Shattuck Labs, Inc. | 7.53% | 515.6K | $1.2M | +0.00%(+0) | $5.22(-35.78%) | 2025-09-30 | |
| LYEL | Lyell Immunopharma, Inc. | 5.45% | 54.9K | $891K | +33.33%(+13.72K) | $17.32(+102.55%) | 2025-09-30 | |
| AMWL | American Well Corporation | 2.92% | 77.7K | $478K | +0.00%(+0) | $25.27(-82.00%) | 2025-09-30 | |
| RANI | Rani Therapeutics Holdings, Inc. | 0.62% | 203.2K | $102K | +0.00%(+0) | $2.62(-46.57%) | 2025-09-30 | |
| LAB | Standard Biotools, Inc. | 0.13% | 16.5K | $21K | +0.00%(+0) | $2.09(-33.83%) | 2025-09-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (7 quarters) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — | -9.12% |
| Top 20 Holdings Unweighted | — | — | — | — | +5.93% |
Takeda Pharmaceutical Co Ltd reports $16.37M in US-listed equity holdings across 8 positions in its most recent 13F filing. Its largest disclosed positions are OVID (59.8%), EQ (15.9%) and XLO (7.6%). The top 20 holdings account for 100% of reported assets. Its disclosed equity book has returned -9.12% cumulatively over 7 quarters. Figures reflect the Q3 2025 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Takeda Pharmaceutical Co Ltd, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Takeda Pharmaceutical Co Ltd’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1395064). View Takeda Pharmaceutical Co Ltd’s 13F filings on SEC